ANAPTYSBIO, INC
ANAB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ANAB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ANAB
AnaptysBio is a clinical-stage biotechnology company developing immune cell modulating antibodies for autoimmune and inflammatory diseases, with lead programs in rheumatoid arthritis, ulcerative colitis, and atopic dermatitis, and a collaboration with GSK in immuno-oncology.
Key risk: Clinical trial delays or failures
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.67B
Cash Runway
34.0 moLead Asset
ANB033 (Phase 1)
Next Catalyst
Phase3_Topline · Mar 30, 2027Financial data as of Mar 31, 2026.
Tracking 5 pipeline candidates · 8 clinical trials · 1 catalyst for ANAPTYSBIO, INC.
Similar companies
AnaptysBio is a clinical-stage biotechnology company developing immune cell modulating antibodies for autoimmune and inflammatory diseases, with lead programs in rheumatoid arthritis, ulcerative colitis, and atopic dermatitis, and a collaboration with GSK in immuno-oncology.
- AnaptysBio is developing wholly owned checkpoint agonists: rosnilimab (PD-1 agonist) in Phase 2b for RA and Phase 2 for UC, and ANB032 (BTLA agonist) in Phase 2b for atopic dermatitis [sec · filed 2024-04-24].
- The company has a financial collaboration with GSK for immuno-oncology, including Jemperli (dostarlimab) and cobolimab, from which it recognizes milestone and royalty revenue [sec · filed 2025-04-29].
- Cash, cash equivalents, and investments totaled $248.5M as of March 31, 2026 [sec].
- Total revenue was $25.6M and net loss was -$52.9M for the latest reported period as of March 31, 2026 [sec].
- ANB032 Phase 2b data showed a favorable safety profile but higher-than-historical placebo rates in the U.S. [sec · filed 2024-12-11].
What works
- AnaptysBio has a diversified pipeline of immune-modulating antibodies targeting multiple autoimmune indications (RA, UC, AD) with two programs in Phase 2b [sec · filed 2024-04-24].
- The GSK collaboration provides a source of milestone and royalty revenue, validating the company's discovery platform [sec · filed 2025-04-29].
- ANB032 demonstrated a favorable safety and tolerability profile with no dose-related safety signals in its Phase 2b trial [sec · filed 2024-12-11].
What to weigh
- The company has a history of net losses, with a net loss of -$52.9M for the three months ended March 31, 2026 [sec].
- ANB032 Phase 2b results showed higher-than-historical placebo rates in the U.S., which may complicate interpretation of efficacy [sec · filed 2024-12-11].
- The company's future funding requirements depend on many uncertain factors, including clinical trial costs and regulatory outcomes [sec_mda · as of 2026-03-03].
From the filings
Quoted directly from source documents.
AnaptysBio is developing rosnilimab (PD-1 agonist) and ANB032 (BTLA agonist) for autoimmune diseases.
“rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis ("RA") and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis ("UC"); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis ("AD")”
SEC filings · April 24, 2024
AnaptysBio has a collaboration with GSK for immuno-oncology antibodies.
“We have also discovered multiple therapeutic antibodies licensed to GlaxoSmithKline, Inc. ("GSK") in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889)”
SEC filings · April 29, 2025
ANB032 was well tolerated with no safety signals in Phase 2b.
“ANB032 was well tolerated across all doses with no safety signals observed. Consistent with prior studies, data demonstrate a favorable safety and tolerability profile for ANB032”
SEC filings · December 11, 2024
Catalyst timeline
- 2027-03-30 · Phase3_Topline — Phase 3 Topline: A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlima — Top-line results from the Phase 3 study of cobolimab in combination with dostarlimab and docetaxel will be reported.
Risks & what to watch (4)›
Key risks
- Clinical trial delays or failures — Product candidates may fail or suffer delays, impacting development timelines and funding needs [sec_mda · as of 2026-03-03].
- Reliance on GSK collaboration — Revenue from GSK milestones and royalties may not continue if partnered programs do not succeed [sec · filed 2025-04-29].
- High placebo rates in trials — ANB032 Phase 2b showed higher-than-historical placebo rates in the U.S., complicating efficacy assessment [sec · filed 2024-12-11].
- Capital consumption and net losses — Net loss of $52.9M in Q1 2026 and accumulated deficit may require future financing [sec].
What to watch
- Top-line data from the rosnilimab Phase 2b RA trial, expected mid-2025 [sec · filed 2024-04-24].
- Top-line data from the rosnilimab Phase 2 UC trial, expected first half of 2026 [sec · filed 2024-04-24].
- Phase 3 top-line data for cobolimab + dostarlimab + docetaxel expected March 30, 2027 [upcoming catalysts].
- Progress of early-stage programs ANB033 (Phase 1) and ANB101 (Phase 1) [sec · filed 2025-04-29].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run ANAPTYSBIO, INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ANAPTYSBIO, INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
34.0 months
D/E 24.86 · 0% dilution
Lead: Approved
5 candidates
1 upcoming, next in ~212d
0 buys · 13 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
204
Total value held
$1.14B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,706,302 | $94.6M |
| blackrock, inc. | 1,681,380 | $93.2M |
| tang capital management llc | 1,330,879 | $73.8M |
| morgan stanley | 993,905 | $55.1M |
| state street corp | 992,445 | $55.0M |
| affinity asset advisors, llc | 940,000 | $52.1M |
| woodline partners lp | 688,512 | $38.2M |
| palo alto investors lp | 638,161 | $35.4M |
| 683 capital management, llc | 625,000 | $34.7M |
| d. e. shaw & co., inc. | 579,296 | $32.1M |
Showing top 10 of 204 institutional holders of ANAPTYSBIO, INC. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 22.1%
- Days to cover
- 6.3
- Shares short
- 4,461,532
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ANAB short interestGovernance
Frequently asked questions
What is the AI investment thesis for ANAPTYSBIO, INC?
AnaptysBio is a clinical-stage biotechnology company developing immune cell modulating antibodies for autoimmune and inflammatory diseases, with lead programs in rheumatoid arthritis, ulcerative colitis, and atopic dermatitis, and a collaboration with GSK in immuno-oncology.
What is ANAPTYSBIO, INC's lead drug candidate?
ANAPTYSBIO, INC's most advanced tracked candidate is ANB033 (Phase 1) for celiac disease and eosinophilic esophagitis.
What is ANAPTYSBIO, INC's next catalyst?
ANAPTYSBIO, INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlima" — expected March 30, 2027.
Who is the CEO of ANAPTYSBIO, INC?
Mr. Daniel R. Faga is the chief executive officer of ANAPTYSBIO, INC (ANAB).
Where is ANAPTYSBIO, INC headquartered?
ANAPTYSBIO, INC (ANAB) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.